ALX Oncology Appoints Allison Dillon as Chief Business Officer [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer. With multiple clinical study readouts over the next 12 months, Allison's deep oncology market expertise and impressive track record in executing portfolio, development, and commercial strategy will be vital in our endeavor to propel evorpacept to its full potential as a first-in-class, universal combination agent with anti-cancer antibodies, antibody-drug conjugates, and checkpoint inhibitors.” “Evorpacept has immense potential to positively impact the lives of people with cancer,” said Dr. Dillon, CBO of ALX O
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- ALX Oncology Appoints Allison Dillon as Chief Business OfficerGlobeNewswire
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerGlobeNewswire
ALXO
Earnings
- 5/9/24 - Beat
ALXO
Sec Filings
- 5/15/24 - Form 4
- 5/13/24 - Form 144
- 5/9/24 - Form 10-Q
- ALXO's page on the SEC website